Core Viewpoint - Heptagon Pharmaceuticals (2142.HK) saw a 9% increase in stock price, reaching a historical high of HKD 16.06, following a mid-term report showing over 50 times year-on-year profit growth [1] Group 1: Financial Performance - The company reported a mid-term profit growth exceeding 50 times year-on-year, indicating strong financial performance [1] Group 2: Strategic Investments - Singapore's Government Investment Corporation (GIC) participated in a placement as a strategic investor on August 29, investing approximately HKD 511 million to acquire 45.022 million shares [1] - This marks the second major global institution to heavily invest in Heptagon Pharmaceuticals this year, following AstraZeneca's strategic investment in March, where it subscribed to 9.15% of newly issued shares at approximately HKD 10.74 per share, a 37.2% premium over the closing price on the day of the agreement [1]
港股异动丨和铂医药大涨9%创历史新高，再获顶级主权基金增持